Form S-8 Regulus Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
January 30, 2017 7:28 AM ESTNeedham & Company downgraded Regulus Therapeutics (NASDAQ: RGLS) from Buy to Hold.
Analyst Alan Carr commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17.... More
